Lukas Heukamp
Overview
Explore the profile of Lukas Heukamp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
2498
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chinczewski L, Harter P, Heukamp L, Mayr D, Grimm C, Heinzelmann-Schwarz V, et al.
Arch Gynecol Obstet
. 2025 Mar;
PMID: 40069521
Introduction: Homologous recombination deficiency (HRD) is a key biomarker in the management of high-grade serous ovarian cancer (HGSOC), guiding treatment decisions, particularly regarding the use of poly(ADP-ribose) polymerase inhibitors (PARPi)....
2.
Wagner J, Roeper J, Heukamp L, Falk M, Willborn K, Griesinger F
Biomedicines
. 2024 Mar;
12(3).
PMID: 38540301
Background: The PACIFIC study showed that after radio-chemotherapy, patients with NSCLC derived a benefit in PFS and OS when treated with durvalumab. This effect was limited to patients with a...
3.
Geers B, Hagenstein J, Endig J, Ulrich H, Fleig L, Sprezyna P, et al.
Cells
. 2022 Sep;
11(17).
PMID: 36078047
Interleukin-2 is central to the induction and maintenance of both natural (nT) and induced Foxp3-expressing regulatory T cells (iT). Thus, signals that modulate IL-2 availability may, in turn, also influence...
4.
Wiesweg M, Preuss C, Roeper J, Metzenmacher M, Eberhardt W, Stropiep U, et al.
Eur J Cancer
. 2021 Apr;
149:211-221.
PMID: 33872981
Objective: BRAF mutations have been subtyped in three functional classes with different oncogenic modes of action. The clinical impact of BRAF mutational subtypes in non-small-cell lung cancer (NSCLC) remains to...
5.
Frost N, Christopoulos P, Kauffmann-Guerrero D, Stratmann J, Riedel R, Schaefer M, et al.
Ther Adv Med Oncol
. 2021 Feb;
13:1758835920980558.
PMID: 33613692
Introduction: We report on the results of the German early access program (EAP) with the third-generation ALK- and ROS1-inhibitor lorlatinib. Patients And Methods: Patients with documented treatment failure of all...
6.
Wagener-Ryczek S, Heydt C, Suptitz J, Michels S, Falk M, Alidousty C, et al.
BMC Cancer
. 2020 May;
20(1):408.
PMID: 32397977
Background: Over the past years, EGFR tyrosine kinase inhibitors (TKI) revolutionized treatment response. 1st-generation (reversible) EGFR TKI and later the 2nd -generation irreversible EGFR TKI Afatinib were aimed to improve...
7.
Michels S, Massuti B, Schildhaus H, Franklin J, Sebastian M, Felip E, et al.
J Thorac Oncol
. 2019 Apr;
14(7):1266-1276.
PMID: 30978502
Introduction: ROS1 rearrangements are found in 1% of lung cancer patients. Therapeutic efficacy of crizotinib in this subset has been shown in early phase trials in the United States and...
8.
Klenke S, Akdeli N, Stelmach P, Heukamp L, Schulte J, Bachmann H
BMC Cancer
. 2019 Mar;
19(1):243.
PMID: 30885150
Background: High-risk neuroblastoma with N-Myc amplification remains a therapeutic challenge in paediatric oncology. Antagonism of pro-death Bcl-2 homology (BH) proteins to pro-survival BH members such as Mcl-1 and Bcl-2 has...
9.
Michels S, Scheel A, Wundisch T, Heuckmann J, Menon R, Puesken M, et al.
NPJ Precis Oncol
. 2018 Jun;
1(1):4.
PMID: 29872693
Inflammatory myofibroblastic tumors are rare mesenchymal neoplasms frequently harboring oncogenic chromosomal rearrangements, most commonly, involving the (anaplastic lymphoma kinase) gene. Treatment of this molecularly defined subgroup with the anaplastic lymphoma...
10.
Mahjoubi L, Cecchi F, Massard C, Calabro F, Gazzah A, Bahleda R, et al.
Tumori
. 2018 May;
104(6):NP38-NP41.
PMID: 29714649
Introduction: Diffuse gastric cancer is associated with poor prognosis. We report a patient with metastatic gastric linitis plastica harboring human epidermal growth factor receptor 2 () activating mutation and amplification....